Horizon Flexible Income ETF
Chicago Board Options ExchangeRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Horizon Flexible Income ETF (FLXN) is an actively managed exchange-traded fund that seeks current income by investing primarily in non-investment grade, high-yield fixed-income instruments, including high-yield bonds and other debt securities; it employs put spread overlays to enhance return potential and manage downside risk through tactical allocations based on market conditions. The fund, issued by Horizons ETF Trust and managed by Horizon Investments, LLC in collaboration with co-manager Exchange Traded Concepts, LLC, concentrates on opportunities in the high-yield debt space with flexibility to adjust holdings dynamically. Launched on July 2, 2025, and listed on Cboe BZX, it operates from the issuer's base at 625 Madison Avenue, 3rd Floor, New York, NY, with Horizon Investments headquartered in Charlotte, North Carolina, targeting financial advisors and investors seeking income-focused strategies in fixed-income markets. In July 2025, Horizon Investments simultaneously launched the companion Horizon Core Bond ETF (BNDY), expanding its actively managed ETF lineup to address advisor demands for innovative fixed-income solutions amid complex interest rate and credit environments; this followed three prior ETF introductions the previous week and preceded further 2025 expansions, culminating in a total of 12 new ETFs by December 2025, including recent additions like Horizon International Equity ETF (FRGN), Small/Mid Cap Core Equity ETF (SMOX), and International Managed Risk ETF (SFTX). The fund maintains an expense ratio of 0.80%, holds a concentrated portfolio of approximately six high-yield fixed-income positions, and serves U.S. investors through goals-based investment approaches provided by Horizon's broader platform of customized SMAs, OCIO services, and technology solutions.
SHAREHOLDER ALERT: WeissLaw LLP Reminds DWSN, PAE, XLRN, and FLXN Shareholders About Its Ongoing Investigations
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates FTSI, UMPQ, FLXN, ADMS; Shareholders are Encouraged to Contact the Firm
SHAREHOLDER ALERT: WeissLaw LLP Reminds ADMS, FLXN, AZPN, and EBMT Shareholders About Its Ongoing Investigations
Flexion (FLXN) to Report Q3 Earnings: What's in the Cards?
Flexion Therapeutics: Bullish On The Buyout
SHAREHOLDER ALERT: WeissLaw LLP Investigates Flexion Therapeutics, Inc.
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Flexion Therapeutics, Inc.
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into the Fairness of the Merger of Flexion Therapeutics, Inc. with Pacira BioSciences, Inc.
Shareholder Alert: Ademi LLP investigates whether Flexion Therapeutics, Inc. has obtained a Fair Price in its transaction with Pacira
Flexion Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Flexion Therapeutics, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – FLXN
FLXN Stock: Why It Substantially Increased Today
Flexion Therapeutics shares soar 39% premarket on news to be acquired by Pacira Biosciences
Pacira BioSciences to Acquire Flexion Therapeutics Further Expanding Leadership Position in Non-Opioid Pain Management
Pacira BioSciences to Acquire Flexion Therapeutics Further Expanding Leadership Position in Non-Opioid Pain Management
Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Flexion Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
Flexion Therapeutics to Present at the Wells Fargo 2021 Virtual Healthcare Conference
Flexion Therapeutics Announces Inclusion of ZILRETTA® in American Academy of Orthopaedic Surgeons (AAOS) Clinical Practice Guidelines for the Management of Osteoarthritis of the Knee
Flexion Therapeutics (FLXN) Upgraded to Buy: Here's What You Should Know
Why Is Flexion Therapeutics (FLXN) Stock Gaining On Wednesday?